We are live on ! Find out more
HCWB icon

HCW Biologics
HCWB

17 hedge funds and large institutions have $1.3M invested in HCW Biologics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

31% more funds holding

Funds holding: 13 → 17 (+4)

28% more capital inflows, than outflows

Capital inflows: $322K | Capital outflows: $250K

0.14% more ownership

Funds ownership: 2.82% → 2.96% (+0.14%)

Holders
17
Holders Change
+4
Holders Change %
+30.77%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Avantax Planning Partners
Avantax Planning Partners
Iowa
+$255K
2
AE Wealth Management
AE Wealth Management
Kansas
+$42.6K
3
Citadel Advisors
Citadel Advisors
Florida
+$14.7K
4
Bridgeway Capital Management
Bridgeway Capital Management
Texas
+$3.07K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.73K

Top Sellers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
-$249K
2
BlackRock
BlackRock
New York
-$1.02K
3
Two Sigma Investments
Two Sigma Investments
New York
-$341

HCWB Hedge Fund Activity: Q4 2023 in Review

17 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q4 2023, worth a combined $1.3M — down 33% from $1.93M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new HCWB positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $255K. The largest seller was HighTower Advisors, cutting an estimated $249K.

  • 17 institutional investors held HCW Biologics (HCWB) as of Q4 2023, up from 13 in Q3 2023.
  • Funds reported $1.3M of HCW Biologics stock for Q4 2023, down 33% quarter-over-quarter.
  • 4 funds opened new HCW Biologics positions in Q4 2023 and 0 closed out, a net change of +4 holders.
  • The largest HCW Biologics buyer in Q4 2023 was Avantax Planning Partners, an estimated $255K added.
  • The largest HCW Biologics seller in Q4 2023 was HighTower Advisors, an estimated $249K sold.

Based on aggregated 13F filings for Q4 2023.